These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 24246428)

  • 21. Antivenoms.
    Theakston RD; Smith DC
    BioDrugs; 1997 May; 7(5):366-75. PubMed ID: 18031100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Report of a WHO workshop on the standardization and control of antivenoms.
    Theakston RD; Warrell DA; Griffiths E
    Toxicon; 2003 Apr; 41(5):541-57. PubMed ID: 12676433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.
    Gutiérrez JM; León G; Lomonte B
    Clin Pharmacokinet; 2003; 42(8):721-41. PubMed ID: 12846594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms.
    Otero R; Gutiérrez JM; Rojas G; Núñez V; Díaz A; Miranda E; Uribe AF; Silva JF; Ospina JG; Medina Y; Toro MF; García ME; León G; García M; Lizano S; De La Torre J; Márquez J; Mena Y; González N; Arenas LC; Puzón A; Blanco N; Sierra A; Espinal ME; Lozano R
    Toxicon; 1999 Jun; 37(6):895-908. PubMed ID: 10340829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production.
    Rojas G; Jiménez JM; Gutiérrez JM
    Toxicon; 1994 Mar; 32(3):351-63. PubMed ID: 8016856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Purification of equine whole IgG snake antivenom by using an aqueous two phase system as a primary purification step.
    Vargas M; Segura Á; Villalta M; Herrera M; Gutiérrez JM; León G
    Biologicals; 2015 Jan; 43(1):37-46. PubMed ID: 25458474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venoms, antivenoms and immunotherapy.
    Chippaux JP; Goyffon M
    Toxicon; 1998 Jun; 36(6):823-46. PubMed ID: 9663690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human heterophilic antibodies against equine immunoglobulins: assessment of their role in the early adverse reactions to antivenom administration.
    León G; Segura A; Herrera M; Otero R; França FO; Barbaro KC; Cardoso JL; Wen FH; de Medeiros CR; Prado JC; Malaque CM; Lomonte B; Gutiérrez JM
    Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1115-9. PubMed ID: 18561967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragmentation of immunoglobulin G.
    Andrew SM; Titus JA
    Curr Protoc Cell Biol; 2003 Feb; Chapter 16():Unit 16.4. PubMed ID: 18228421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal conditions for the preparation of Fab and F(ab')2 fragments from monoclonal IgG of different rat IgG subclasses.
    Rousseaux J; Rousseaux-Prévost R; Bazin H
    J Immunol Methods; 1983 Nov; 64(1-2):141-6. PubMed ID: 6644029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A protocol for 'enhanced pepsin digestion': a step by step method for obtaining pure antibody fragments in high yield from serum.
    Jones RG; Landon J
    J Immunol Methods; 2003 Apr; 275(1-2):239-50. PubMed ID: 12667687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use.
    Ismail M; Abd-Elsalam MA
    Toxicon; 1998 Nov; 36(11):1523-8. PubMed ID: 9792168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation of F(ab')2 fragments from monoclonal mouse IgG1 suitable for use in radioimaging.
    Kurkela R; Vuolas L; Vihko P
    J Immunol Methods; 1988 Jun; 110(2):229-36. PubMed ID: 3132507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation.
    García M; Monge M; León G; Lizano S; Segura E; Solano G; Rojas G; Gutiérrez JM
    Biologicals; 2002 Jun; 30(2):143-51. PubMed ID: 12127316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fragmentation of immunoglobulin G.
    Andrew SM; Titus JA
    Curr Protoc Immunol; 2001 May; Chapter 2():Unit 2.8. PubMed ID: 18432772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of pepsin digestion on the antivenom activity of equine immunoglobulins.
    Morais V; Massaldi H
    Toxicon; 2005 Dec; 46(8):876-82. PubMed ID: 16260020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of ovine and equine antivenoms.
    Sjostrom L; al-Abdulla IH; Rawat S; Smith DC; Landon J
    Toxicon; 1994 Apr; 32(4):427-33. PubMed ID: 8052997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab')2 antivenoms.
    Boyer LV; Chase PB; Degan JA; Figge G; Buelna-Romero A; Luchetti C; Alagón A
    Toxicon; 2013 Nov; 74():101-8. PubMed ID: 23948058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation of F(ab')
    Ismael BN; Abass KS; Khalil KA; Salih KA
    Biologicals; 2018 Nov; 56():19-23. PubMed ID: 30153952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralization of the neuromuscular inhibition of venom and taipoxin from the taipan (Oxyuranus scutellatus) by F(ab')2 and whole IgG antivenoms.
    Herrera M; de Cássia de O Collaço R; Villalta M; Segura Á; Vargas M; Wright CE; Paiva OK; Matainaho T; Jensen SD; León G; Williams DJ; Rodrigues-Simioni L; Gutiérrez JM
    Toxicol Lett; 2016 Jan; 241():175-83. PubMed ID: 26621539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.